FAQ on Lantern Pharma Inc.'s AI Tool for Predicting Cancer Drug Combinations Efficacy

What is the new AI tool launched by Lantern Pharma Inc.?

Lantern Pharma Inc. has introduced an AI-powered module within its RADR(R) platform designed to predict the effectiveness of cancer treatment combinations involving DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis).

How does the AI tool predict the efficacy of cancer drug combinations?

The module uses genomic, transcriptomic, and clinical data to predict treatment synergy and patient response, supported by a review of 221 clinical trials to inform its predictive algorithm.

What cancer type is the AI tool’s first application targeting?

The AI tool supported the design of Lantern’s FDA-cleared Phase 1B/2 trial in triple-negative breast cancer.

Why is the launch of this AI tool significant?

The launch is significant as it comes at a time when the global market for combination cancer therapies is projected to surpass $50 billion by 2030, offering a novel approach to oncology drug development.

What data supports the development of the AI tool’s predictive algorithm?

A review of 221 clinical trials informed the development of the predictive algorithm, with non-PARP DDRi combinations with DNA-damaging agents showing strong outcomes in specific cancer subtypes.

Is Lantern Pharma planning to commercialize the AI module for broader use?

Yes, Lantern is evaluating licensing opportunities to commercialize the module for broader oncology use beyond its initial application.

Where can investors find the latest news and updates about Lantern Pharma Inc.?

The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN.

What is the RADR(R) platform?

The RADR(R) platform is Lantern Pharma’s AI-guided drug development platform that now includes the new AI module for predicting the efficacy of cancer drug combinations.

How can the AI tool impact the future of cancer treatment?

By accurately predicting the efficacy of drug combinations, the AI tool can streamline the development of more effective cancer therapies, potentially improving patient outcomes and reducing the time and cost associated with drug development.